ID: ALA193421

Max Phase: Preclinical

Molecular Formula: C19H21N5O4

Molecular Weight: 383.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  OC[C@H]1O[C@@H](n2cnc3c(NC4CC4c4ccccc4)ncnc32)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C19H21N5O4/c25-7-13-15(26)16(27)19(28-13)24-9-22-14-17(20-8-21-18(14)24)23-12-6-11(12)10-4-2-1-3-5-10/h1-5,8-9,11-13,15-16,19,25-27H,6-7H2,(H,20,21,23)/t11?,12?,13-,15-,16-,19-/m1/s1

Standard InChI Key:  GAIXIJBBHRACLL-UIKOTCIDSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 383.41

Molecular Weight (Monoisotopic): 383.1594

AlogP: 0.41

#Rotatable Bonds: 5

Polar Surface Area: 125.55

Molecular Species: NEUTRAL

HBA: 9

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.45

CX Basic pKa: 3.72

CX LogP: 0.18

CX LogD: 0.17

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.50

Np Likeness Score: 0.55

References

1. Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, Jacobson KA..  (2005)  (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.,  48  (6): [PMID:15771421] [10.1021/jm049580r]

2. Baraldi PG, Preti D, Borea PA, Varani K..  (2012)  Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.,  55  (12): [PMID:22468757] [10.1021/jm300087j]

Source

Source(1):

• Scientific Literature